Scientists at La Jolla Institute identify histamine releasing factor molecule as a promising target for developing new treatments for asthma and allergies. The discovery provides new insights on the role of HRF in promoting asthma and some allergies, including its receptor.
Researchers at La Jolla Institute have identified a previously unknown molecular interaction between protein kinase C theta and CD28 that is essential for T lymphocyte activation. This discovery opens up a novel therapeutic avenue for autoimmune diseases such as multiple sclerosis and rheumatoid arthritis by blocking the cellular inter...
Researchers at the La Jolla Institute identified a previously unknown mechanism generating protective immune memory cells to fight recurring infections at mucosal linings. This discovery could lead to the creation of new and more effective vaccines by triggering the newly identified mechanism, particularly for Listeria and HIV.
The La Jolla Institute's new RNAi Center will focus on understanding the genetics behind disease processes and developing new therapies to treat disease. The Center aims to make key discoveries about how the immune system recognizes bacteria and viruses and fights infections.
The La Jolla Institute has identified LIGHT as a promising therapeutic target for chronic asthma, COPD, and other lung conditions. Blocking LIGHT's interactions with its receptors significantly inhibited airway remodeling in mouse models of chronic asthma.
A La Jolla Institute-led team has identified the primary cellular players in an adenosine-fueled inflammation cascade that contributes to insulin resistance. By using an adenosine receptor blocker, the team prevented the activation of macrophages, leading to improved insulin sensitivity and reduced blood sugar levels in diabetic animals.
A La Jolla Institute team has validated a computer model's ability to predict key information on nasal insulin treatment regimens in type 1 diabetes. The platform accurately predicted biomarker onset and therapeutic outcome, confirming its potential as a valuable research tool.
The La Jolla Institute will host research projects throughout the San Diego biomedical community, exploring genetic triggers of disease and developing new therapies for cancer and other diseases. The Center is expected to propel immunology research and catalyze a broad base of basic and clinical investigations.
Researchers are testing Lexiscan, a pharmacologic stress agent, in a multicenter clinical trial to reduce inflammation in sickle cell disease. The trial aims to improve symptoms such as pain and breathing problems, which can be fatal.
Researchers have proven that subneutralizing levels of dengue virus antibodies exacerbate the disease, contradicting the normal function of antibodies. This finding has major implications for developing a vaccine against dengue virus, which annually infects 50-100 million people worldwide.
The La Jolla Institute will receive funding to identify epitopes for developing effective vaccines against these diseases. The study aims to make new inroads toward vaccines that can target the body's immune system to launch an attack, with potential applications for tuberculosis and malaria.
Researchers at the La Jolla Institute found that previous influenza infections can provide some level of immunity to the H1N1 'swine' flu. The study suggests that this pre-existing immunity may make the disease less severe in the general population, reducing its impact.
Hilde Cheroutre's groundbreaking proposal aims to pinpoint molecular events underlying autoimmunity susceptibility, enabling early detection and potentially preventing the disease. Her innovative approach could also lead to new therapies for those at high risk or already affected by autoimmunity.
Researchers at the La Jolla Institute have identified a previously unknown role of an enzyme in suppressing tumor growth, which may lead to new treatments for myeloproliferative diseases and certain types of leukemia. The discovery could also provide insights into the mechanisms underlying blood cancers.
Researchers at La Jolla Institute have discovered the specific gene that triggers antibody production, a key step in mounting an immune response against viruses and pathogens. The finding has significant implications for developing new and more effective vaccines.
Researchers at La Jolla Institute have identified a cellular defect that increases the risk of severe reactions to the smallpox vaccine in people with eczema. Boosting Natural Killer cell activity may help prevent such reactions.
The Immune Epitope Database and Analysis Resource (IEDB) is the world's largest collection of scientific data on how the immune system responds to infectious diseases. With its 2.0 launch, researchers worldwide can now easily access and analyze over 95% of published information on immune epitope responses.
A study published in Proceedings of the National Academy of Sciences shows that natural killer (NK) T cells play a crucial role in preventing chronic inflammatory infection and clearing Borrelia burgdorferi bacteria, which cause Lyme disease. The research demonstrates that NK T cells are central to reducing arthritis symptoms.
Scientists at La Jolla Institute for Immunology discovered a previously unknown mechanism in how the body responds to viruses, illuminating a new approach to developing vaccines. The finding reveals that B cells and CD4 T cells recognize the same piece of the virus, narrowing down the search for antigens.
A major five-year study will analyze 32 common allergen sources, identifying T cell responses and potential epitope-based therapies. The project may lead to revolutionary new approaches for treating allergies, potentially reducing the need for lengthy desensitization treatments.
Researchers at LIAI demonstrated that retinoic acid regulates inflammation in laboratory mice, affecting pro-inflammatory T cell lineages. This finding suggests a new avenue of therapies using retinoic acid to treat autoimmune diseases.
Researchers at La Jolla Institute for Allergy & Immunology have made an important finding on cytomegalovirus transmission by reducing the virus in salivary glands using antibodies. The study may have implications for other chronic virus infections like hepatitis and HIV.
The La Jolla Institute completed a first-of-its-kind study analyzing all published data worldwide on influenza A virus antibody and T cell epitopes. The study provides critical information for developing vaccines and therapies against both seasonal and pandemic influenza strains.
Researchers at LIAI have identified Borrelia burgdorferi's glycolipid as an immune system trigger for fighting Lyme disease. This discovery could lead to the development of a new vaccine against the tick-borne disorder.
The study demonstrates an extremely high rate of prediction accuracy (95%) in a very complex pathogen, the vaccinia virus. Bioinformatics was able to reveal the vast majority of epitopes that trigger an effective immune response against the virus.
Researchers at La Jolla Institute for Immunology have made a major finding on a potential cure for type 1 diabetes by combining two therapies, producing better efficacy and longer-lasting results in preclinical trials. The combination therapy is being planned to begin human clinical trials later this year.
Researchers have identified a protein in the smallpox virus that elicits a strong human antibody response, providing potential protection against the lethal virus. The discovery could lead to the development of an effective treatment for smallpox, offering immediate protection to individuals at risk.
The study found a cellular protein called HVEM acts as an 'off and on switch' for immune responses, enabling communication between T lymphocytes and other cells. This discovery could lead to new treatments for autoimmune diseases by mimicking HVEM's action.